Small molecule therapeutic approach to treat PSP and Parkinson’s






Phosphorylated tau enters mitochondria and drives reverse electron transport at Complex I. RET in turn drives more tau phosphorylation, so every turn of the loop makes more p-tau.
Li, Rimal, Bhurtel, Yeung, B.G. Lu, Grinberg, Spina, Cobos Sillero, Seeley, Guo & Lu · Stanford University and UCSF · Read the full study
Source: Li et al., Neuron 2026. Mice dosed orally for 2–4 months (rTg4510 tauopathy model). Patient tissue from the UCSF Memory & Aging Center and Stanford brain bank. The paper’s “CPT” is CP-235.
Progressive supranuclear palsy: the fastest, cleanest clinical read on the mechanism
~30,000 US: CurePSP (likely an underestimate given frequent misdiagnosis). Li et al., Neuron 2026.
Two established drivers of Parkinson’s converge on reverse electron transport, and oral CP-235 acts on both
Complex I deficiency in the Parkinson’s substantia nigra is well documented, and MPTP and rotenone, the toxins that model the disease, both inhibit Complex I.
SNCA mutations cause Parkinson’s, and phosphorylated α-synuclein is the hallmark of Lewy pathology. A Complex I insult alone is enough to raise it: phosphorylated α-synuclein rises in the MPTP model.
Source: Bhurtel, Rimal, Li & Lu, Molecular Neurodegeneration Advances 2026. The paper’s “CPT” is CP-235.